DMK Pharmaceuticals Corporation, based in San Diego, disclosed a third-quarter net loss of $1.4 million today. The biopharmaceutical company reported a loss of 20 cents per share, which widened to 25 cents after adjustments for discontinued operations. Revenue for the quarter was also revised, coming in at $9,000 from the initially reported $9,100.
The financial results were part of an announcement made by the company on Tuesday, which also highlighted its approach to generating revenue through a subscription model. This model allows for one free monthly story view with additional access upon account registration. The subscription proceeds are allocated to support community projects.
InvestingPro Insights
According to real-time data from InvestingPro, DMK Pharmaceuticals Corporation's stock price has seen a decline of 3% over the last twelve months as of Q3 2023. Despite this, the company's earnings per share (EPS) are projected to see a rise of 5% in the forthcoming Q4 2023. Furthermore, the company's revenue growth rate for the next fiscal year is anticipated to be around 10%. An InvestingPro tip for investors is to monitor the company's EPS growth closely, as it could be a potential indicator of profitability in the future. Another InvestingPro tip is to keep an eye on the projected revenue growth rate, which could be a sign of recovery. InvestingPro offers many more such insightful tips to its users. For instance, there are currently 15 additional tips listed on the InvestingPro platform specifically related to DMK Pharmaceuticals Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.